Does FTC Health Ads Guide Read Like Rulemaking, Ignore Court Decisions On Requiring RCTs?
Executive Summary
“I'm not sure they shouldn’t have done a notice of proposed rulemaking,” says attorney Claudia Lewis. From previous guidance, “the FTC has taken it a step in the different direction that you need robust scientific evidence, in their mind robust scientific evidence means clinical data.”
You may also be interested in...
Attorneys: FTC’s Interpretation Of Penalty Offense Authority Yet To Be Tested In Court
Attorneys are closely watching how the US Federal Trade Commission’s latest wave of penalty offense notices to almost 700 companies plays out, noting – as did recently departed commissioner Christine Wilson – that seeking civil penalties in court under this “long dormant” authority could be challenging.
FTC’s Health Products Guidance: Attorneys Discuss Insistence On RCTs, Implications For Businesses
The updated and expanded guidance embodies the US Federal Trade Commission’s enforcement approach for more than a decade, identifying randomized clinical trials as the competent and reliable scientific evidence needed to back health-related claims. Attorneys from Kelley Drye & Warren, Lathrop GMP and Amin Talati Wasserman weigh in.
FTC Expands Dietary Supplement Advertising Guidance To All Products Making Health-Related Claims
The Federal Trade Commission’s Health Products Compliance Guidance, published 20 December, expands the agency’s focus from dietary supplements to all products making health-related claims, providing the first update in 25 years on the FTC’s thinking on clear and conspicuous disclosures and competent and reliable scientific evidence.